FDA Calendar for AVANIR Pharmaceuticals (AVNR)

| Register (free)
Avanir Pharmaceuticals, Inc. (Avanir) is a pharmaceutical company focused on acquiring, developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company’s lead product candidate, Zenvia (dextromethorphan hydrobromide/quinidine sulfate), has completed three Phase III clinical trials for the treatment of pseudobulbar affect (PBA) and has completed a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain (DPN pain). In addition to its focus on products for the central nervous system, Avanir also has a number of partnered programs in other therapeutic areas. Its product, docosanol 10% cream, (sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Zenvia Pain Management UnknownPhase 3
Nuedexta Other ApprovedNDA


Events

No future events listed at this time, please check back later.
2 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

AVNR

$3.31
0.07 +2.16%
2/3/2012 4:00:00 PM

Sponsors

Other Links